Long-lasting effects of serotonin deficiency on differentiating peptidergic neurons in the rat suprachiasmatic nucleus.
Serotonin (5-HT, 5-hydroxytryptamine) is known to be an inductor of the brain development [Whitaker-Azmitia, P.M., Druse, M., Walker, P., Lauder, J.M., 1996. Serotonin as a developmental signal. Behav. Brain Res. 73, 19-29; Ugrumov, M.V., 1997. Hypothalamic monoaminergic systems in ontogenesis: development and functional significance. Int. J. Dev. Biol. 41, 809-816]. This study was aimed to test whether it provides long-lasting effects on the differentiating vasoactive intestinal polypeptide (VIP) and vasopressin (VP) neurons of the suprachiasmatic nucleus (SCN) in rats. To this aim, 5-HT was depleted in fetal brain by daily injections of p-chlorophenylalanine (pCPA), an inhibitor of 5-HT synthesis, to pregnant rats from the 13th to the 21st day of gestation. Pregnant rats injected with saline served as controls. The offsprings (males) of pCPA-treated and control pregnant rats were maintained after birth for two months under normal laboratory conditions. Then, the SCN was processed for immunocytochemistry of VIP and VP and in situ hybridization of appropriate mRNAs. There were no differences in concentrations of VIP and VP mRNAs in the SCN in adult offsprings of the 5-HT-depleted pregnant rats compared to the controls. Moreover, 5-HT deficiency did not induce any change in size of VIP-immunoreactive (IR) and VP-IR neurons. Conversely, both the numbers of VIP- and VP-immunoreactive neurons and concentrations of the peptides in cell bodies increased significantly. It is concluded that 5-HT provides long-lasting effects on differentiating VIP and VP neurons in the SCN resulting in attenuated release rather than elevated synthesis of both peptides in adulthood.
Mirochnik
V
V
Institute of Normal Physiology, Russian Academy of Medical Sciences, 8 Baltiiskaya str., Moscow 125315, Russia.
Bosler
O
O
Tillet
Y
Y
Calas
A
A
Ugrumov
M
M
D000704:Analysis of Variance; D000818:Animals; D003952:Diagnostic Imaging; D005260:Female; D010134:Fenclonine / Q000633:toxicity; D007150:Immunohistochemistry / Q000379:methods; D017403:In Situ Hybridization / Q000379:methods; D008297:Male; D009474:Neurons / Q000187:drug effects / Q000378:metabolism*; D011247:Pregnancy; D011297:Prenatal Exposure Delayed Effects; D012333:RNA, Messenger / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D012701:Serotonin / Q000172:deficiency*; D013493:Suprachiasmatic Nucleus / Q000166:cytology* / Q000187:drug effects; D013495:Supraoptic Nucleus / Q000166:cytology / Q000378:metabolism; D013995:Time; D014660:Vasoactive Intestinal Peptide / Q000378:metabolism; D014667:Vasopressins / Q000235:genetics / Q000378:metabolism
D012333:RNA, Messenger; D014667:Vasopressins; D012701:Serotonin; D014660:Vasoactive Intestinal Peptide; D010134:Fenclonine